In a stun­ning about face, the FDA is now wel­com­ing the new drug ap­pli­ca­tion from Alk­er­mes it re­ject­ed 2 weeks ago

Some­body at the FDA just got a rude wake up call.

Just two weeks af­ter the FDA in­vit­ed Wall Street to pum­mel Alk­er­mes $ALKS by re­fus­ing to even ac­cept its ap­pli­ca­tions for the de­pres­sion drug ALKS-5461, the biotech says that the agency has sud­den­ly de­cid­ed to sim­ply change its mind.

Ac­cord­ing to Alk­er­mes, the stun­ning about face came af­ter the com­pa­ny “clar­i­fied cer­tain as­pects of the NDA sub­mis­sion. No ad­di­tion­al da­ta or analy­ses were sub­mit­ted by Alk­er­mes to FDA.”

Alk­er­mes shares im­me­di­ate­ly shot up 20%, re­gain­ing $1.3 bil­lion of its mar­ket cap. But it couldn’t hold on to that, though, drop­ping to an 8% gain mid-morn­ing. Its PDU­FA date was set for Jan­u­ary 31, 2019.

Alk­er­mes said in ear­ly April that the FDA was de­mand­ing that the com­pa­ny con­duct ad­di­tion­al tri­als of 5461, a move that ham­mered the com­pa­ny’s share price as an­a­lysts pon­dered the years of work and ex­pense in tak­ing an­oth­er risky shot at gain­ing pos­i­tive clin­i­cal da­ta.

The com­pa­ny was throw­ing the dice on its ap­pli­ca­tion when it first filed, hop­ing to per­suade the FDA that its one pos­i­tive piv­otal study along with ad­di­tion­al da­ta would out­weigh the two failed tri­als that tar­nished the drug. That would not have met the agency’s long es­tab­lished stan­dard for two pos­i­tive stud­ies, but as I’ve writ­ten ear­li­er the FDA has been ratch­et­ing down its hur­dles to get more drugs ap­proved.

The change up marks an­oth­er sign of the dra­mat­ic shift in the FDA’s stance on drug ap­pli­ca­tions and its stan­dards for re­views, rais­ing some ma­jor ques­tions for the in­dus­try as well as con­sumers. Since Scott Got­tlieb be­came com­mis­sion­er in 2017 af­ter he was nom­i­nat­ed for Pres­i­dent Don­ald Trump with a man­date to speed new drug ap­provals, the agency re­versed it­self on three key drug re­jec­tions for Eli Lil­ly, Ther­a­peu­tic­sMD and Am­i­cus, wav­ing off its ear­li­er de­mands for more work.

None of these re­ver­sals car­ry a guar­an­tee of an ap­proval, but they do re­flect changes in di­rec­tion that all drug de­vel­op­ers will pay close at­ten­tion to.

Bar­clays summed it up this way:

Giv­en the po­lit­i­cal na­ture of the cur­rent FDA ad­min­is­tra­tion, we could see a sce­nario where nor­mal-course re­view for ALKS-5461 felt more “ap­pro­pri­ate” than con­tro­ver­sy raised by an RTF, es­pe­cial­ly con­sid­er­ing the prod­uct’s pri­or Fast Track des­ig­na­tion and med­ical need for in­no­va­tion with­in the in­di­ca­tion. How­ev­er, we con­tin­ue to feel ALKS is long from out of the woods on ALKS-5461 and will need to con­tin­ue to en­gage with FDA dur­ing re­view with po­ten­tial for the on­go­ing Phase 3 to play a role in any po­ten­tial ap­proval or re­view de­ci­sion.

Who at the FDA over­ruled the de­ci­sion to re­ject Alk­er­mes’ drug ap­pli­ca­tion? And why?

The agency, bound by strict rules of si­lence when it comes to com­ment­ing on com­pa­nies and drugs out­side a care­ful­ly reg­u­lat­ed set of pub­lic dis­clo­sures, de­clined com­ment — as they al­ways do.

Craig Hop­kin­son

Craig Hop­kin­son, chief med­ical of­fi­cer and se­nior vice pres­i­dent of med­i­cines de­vel­op­ment and med­ical af­fairs at Alk­er­mes had this to say:

“We will con­tin­ue to en­gage with the FDA through­out the re­view process, as we work to bring this im­por­tant med­i­cine to pa­tients.”


Im­age: Alk­er­mes CEO Richard Pops at an End­points event, Jan­u­ary 2017. END­POINTS NEWS

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

Who are the women su­per­charg­ing bio­phar­ma R&D? Nom­i­nate them for this year's spe­cial re­port

The biotech industry has faced repeated calls to diversify its workforce — and in the last year, those calls got a lot louder. Though women account for just under half of all biotech employees around the world, they occupy very few places in C-suites, and even fewer make it to the helm.

Some companies are listening, according to a recent BIO survey which showed that this year’s companies were 2.5 times more likely to have a diversity and inclusion program compared to last year’s sample. But we still have a long way to go. Women represent just 31% of biotech executives, BIO reported. And those numbers are even more stark for women of color.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vicente Anido (University of West Virginia via YouTube)

Aerie fires CEO af­ter lead pro­gram flop, com­ments about pri­ma­ry end­points be­ing 'not re­quired'

Aerie Pharmaceuticals CEO Vicente Anido has left the company less than a week after trying to chart a Phase III study in the wake of a serious Phase IIb flop.

Anido’s last day at Aerie was Friday, the biotech announced in a news release Tuesday morning, and Benjamin McGraw is taking his place in an interim role. The now former CEO was terminated without cause, according to an SEC filing.

The board has started looking for a full-time chief to take his place.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.

When ef­fi­ca­cy is bor­der­line: FDA needs to get more con­sis­tent on close-call drug ap­provals, agency-fund­ed re­search finds

In the exceedingly rare instances in which clinical efficacy is the only barrier to a new drug’s approval, new FDA-funded research from FDA and Stanford found that the agency does not have a consistent standard for defining “substantial evidence” when flexible criteria are used for an approval.

The research comes as the FDA is at a crossroads with its expedited-review pathways. The accelerated approval pathway is under fire as the agency recently signed off on a controversial new Alzheimer’s drug, with little precedent to explain its decision. Meanwhile, top officials like Rick Pazdur have called for a major push to simplify and clarify all of the various expedited pathways, which have grown to be must-haves for sponsors of nearly every newly approved drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.

Jay Bradner (Jeff Rumans for Endpoints News)

Div­ing deep­er in­to in­her­it­ed reti­nal dis­or­ders, No­var­tis gob­bles up an­oth­er bite-sized op­to­ge­net­ics biotech

Right about a year ago, a Novartis team led by Jay Bradner and Cynthia Grosskreutz at NIBR swooped in to scoop up a Cambridge, MA-based opthalmology gene therapy company called Vedere. Their focus was on a specific market niche: inherited retinal dystrophies that include a wide range of genetic retinal disorders marked by the loss of photoreceptor cells and progressive vision loss.

But that was just the first deal that whet their appetite.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.

Take­da snaps up the Japan­ese rights to an old Shire cast-off; Boehringer In­gel­heim ac­quires Abexxa Bi­o­log­ics

A week before the FDA is set to decide on Mirum Pharmaceuticals’ lead liver disease drug — an old Shire cast-off called maralixibat — Takeda is swooping in to secure the rights in Japan.

Maralixibat’s roots trace back to Lumena, which was snapped up by Shire for $260 million-plus back in 2014. While the candidate had failed mid-stage studies at Shire, Mirum believes better trial design and patient selection will deliver the wins it needs. The drug is currently in development for Alagille syndrome (a condition called ALGS in which bile builds up in the liver), progressive familial intrahepatic cholestasis (PFIC, which causes progressive liver disease) and biliary atresia (a blockage in the ducts that carry bile from the liver to the gallbladder).

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Biopharma’s resident antibody-drug conjugate expert Seagen has scored a clutch of oncology approvals in recent years, finding gold in what are known as “third-gen” ADCs. Now, another of their partnered conjugates is ready for prime time.

The FDA on Monday handed an accelerated approval to Seagen and Genmab’s Tivdak (tisotumab vedotin-tftv, or “TV”) in second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy, the companies said in a release.